Carisma Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CARM research report →
About the company
Carisma Therapeutics, Inc. , a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis.
- CEO
- Craig R. Jalbert
- IPO
- 2014
- Employees
- 46
- HQ
- Philadelphia, PA, US
Price Chart
- Market Cap
- $255.25K
- P/E
- 0.03
- P/S
- 0.00
- P/B
- -0.29
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
- Gross Margin
- 98.05%
- Op Margin
- 20.61%
- Net Margin
- 15.28%
- ROE
- -28.86%
- ROIC
- -10330.48%
- Revenue
- $19.63M · 31.59%
- Net Income
- $-60,477,000 · 30.39%
- EPS
- $-1.46 · 43.63%
- Op Income
- $-62,179,000
- FCF YoY
- 27.06%
- 52W High
- $0.56
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.04
- Beta
- -9.34
- Avg Volume
- 44.92K
Get TickerSpark's AI analysis on CARM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 25 | Klichinsky Michael | other | 56,982 |
| Oct 7, 25 | Klichinsky Michael | sell | 56,982 |
| Oct 7, 25 | Klichinsky Michael | other | 56,982 |
| Oct 1, 25 | Klichinsky Michael | sell | 165,000 |
| Oct 2, 25 | Klichinsky Michael | sell | 200,000 |
| Oct 3, 25 | Klichinsky Michael | sell | 119,347 |
| Jan 28, 25 | Klichinsky Michael | other | 221,000 |
| Jan 28, 25 | Kelly Steven | other | 500,000 |
| Jan 1, 25 | McAndrew Natalie | other | 0 |
| Oct 31, 24 | Cheng Sohanya Roshan | other | 38,700 |
Our CARM coverage
Recent articles, reports, and earnings notes.
No research on CARM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CARM report →Similar companies
Peers in the same neighborhood.